Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel

The use of prasugrel in patients with coronary artery disease (CAD) has been associated with decreased major adverse cardiac events (MACEs) compared with clopidogrel but with an increased risk of bleeding. However, it remains unclear if the risks of bleeding outweigh those of MACEs in patients on pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2015-08, Vol.116 (3), p.384-392
Hauptverfasser:	Chen, Hai-Bin, MD, Zhang, Xin-Lu, MD, Liang, Hong-Bin, MD, Liu, Xue-Wei, MD, Zhang, Xin-Yu, MD, Huang, Bao-Yi, MD, Xiu, Jiancheng, MD, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Bias Cardiology Cardiovascular Clinical trials Collaboration Confidence intervals Coronary Artery Disease - drug therapy Global Health Heart attacks Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Incidence Piperazines - adverse effects Piperazines - therapeutic use Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Prasugrel Hydrochloride Purinergic P2Y Receptor Antagonists - adverse effects Purinergic P2Y Receptor Antagonists - therapeutic use Randomized Controlled Trials as Topic Regression analysis Risk Factors Studies Thiophenes - adverse effects Thiophenes - therapeutic use Ticlopidine - adverse effects Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!